Botulinum toxin type A was first used for the treatment of spasticity in 1989. A small uncontrolled study of treatment of upper limb spasticity after stroke reported encouraging benefits, including ...
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the ...
Botulinum toxin therapy has emerged as a pivotal treatment in the management of spasticity, a debilitating neuromuscular condition characterised by increased muscle tone and hyperactive reflexes. By ...
Botulinum toxin is an established antispastic treatment for children with cerebral palsy (CP), but its effect on adductor spasticity—an important risk factor for hip dislocation—has not been ...
DelveInsight's "Muscle Spasticity Pipeline Insight 2025" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Muscle Spasticity pipeline landscape. It covers the ...
Spasticity is a condition that causes your muscles to stiffen, tighten, and contract. It happens involuntarily, which means you don’t have control over it. Spasticity typically happens because of ...
The most common type of CP diagnosed in the premature population is spastic CP. These infants are usually initially hypotonic, with spasticity developing over time. Spasticity is characterized by ...
If you or a loved one have suffered a stroke, a brain or spinal cord injury, or are living with cerebral palsy or multiple sclerosis (MS), you might be familiar with a condition called spasticity, ...
Cerebral palsy can cause muscle spasms and many other hypertonic symptoms. The symptoms can be treated in a variety of ways, often starting with physical therapy. Cerebral palsy (CP) is a group of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results